secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001564590-22-037038
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q3 net loss narrows to $41.9M; APONVIE approved, launch Q1 2023
--------------------------------------------------------------------------------

- Net product sales $26.6M (+15% YoY); net loss $41.9M vs $52.4M YoY; oncology franchise sales $23.9M (+13%).
- ZYNRELEF unit demand grew 18% QoQ; Q4 net sales expected to rise 30-40% QoQ.
- APONVIE (aprepitant) FDA approved Sep 16; U.S. launch planned Q1 2023.
- Completed $75M private placement to strengthen balance sheet; cash $121.7M.
- Full-year 2022 oncology care franchise guidance reaffirmed at $93-95M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/0001564590-22-037038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/hrtx-8k_20221108.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer